World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Diet, n., physical activity and liver cancer. Available at dietandcancerreport.org. Accessed 02/23/2022
Arora, L., Mohan, C. D., Yang, M. H., Rangappa, S., Deivasigamani, A., Kumar, A. P., et al. (2021). Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the STAT3 signaling pathway. Cancers (Basel), 13(21). https://doi.org/10.3390/cancers13215479.
Mohan, C. D., Yang, M. H., Rangappa, S., Chinnathambi, A., Alharbi, S. A., Alahmadi, T. A., et al. (2022). 3-Formylchromone counteracts STAT3 signaling pathway by elevating SHP-2 expression in hepatocellular carcinoma. Biology, 11(1). https://doi.org/10.3390/biology11010029.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A cancer journal for clinicians, 71(3), 209–249.
McGlynn, K. A., Petrick, J. L., & El-Serag, H. B. (2021). Epidemiology of hepatocellular carcinoma. Hepatology, 73, 4–13.
Mastron, J. K., Siveen, K. S., Sethi, G., & Bishayee, A. (2015). Silymarin and hepatocellular carcinoma: A systematic, comprehensive, and critical review. Anti-Cancer Drugs, 26(5), 475–486. https://doi.org/10.1097/cad.0000000000000211
Raghunath, A., Sundarraj, K., Arfuso, F., Sethi, G., & Perumal, E. (2018). Dysregulation of Nrf2 in hepatocellular carcinoma: Role in cancer progression and chemoresistance. Cancers (Basel), 10(12), 481.
Forner, A., Reig, M., & Bruix, J. (2018). Hepatocellular carcinoma. Lancet, 391(10127), 1301–1314. https://doi.org/10.1016/s0140-6736(18)30010-2
Mohan, C. D., Rangappa, S., Nayak, S. C., Sethi, G., & Rangappa, K. S. (2021). Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma. Biochimica et Biophysica Acta - Reviews on Cancer, 1876(1), 188574. https://doi.org/10.1016/j.bbcan.2021.188574
Sajith, A. M., Narasimhamurthy, K. H., Shanmugam, M. K., Rangappa, S., Chandra Nayak, S., Chinnathambi, A., et al. (2021). Pyrimidine-2,4-dione targets STAT3 signaling pathway to induce cytotoxicity in hepatocellular carcinoma cells. Bioorganic & Medicinal Chemistry Letters, 50, 128332. https://doi.org/10.1016/j.bmcl.2021.128332
Mohan, C. D., Kim, C., Siveen, K. S., Manu, K. A., Rangappa, S., Chinnathambi, A., et al. (2021). Crocetin imparts antiproliferative activity via inhibiting STAT3 signaling in hepatocellular carcinoma. IUBMB Life, 73(11), 1348–1362. https://doi.org/10.1002/iub.2555
Colagrande, S., Inghilesi, A. L., Aburas, S., Taliani, G. G., Nardi, C., & Marra, F. (2016). Challenges of advanced hepatocellular carcinoma. World Journal of Gastroenterology, 22(34), 7645.
Swamy, S. G., Kameshwar, V. H., Shubha, P. B., Looi, C. Y., Shanmugam, M. K., Arfuso, F., et al. (2017). Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Targeted Oncology, 12(1), 1–10. https://doi.org/10.1007/s11523-016-0452-7
Chen, X., Tang, F.-R., Arfuso, F., Cai, W.-Q., Ma, Z., Yang, J., et al. (2020). The emerging role of long non-coding RNAs in the metastasis of hepatocellular carcinoma. Biomolecules, 10(1), 66.
Keerthy, H. K., Mohan, C. D., Siveen, K. S., Fuchs, J. E., Rangappa, S., Sundaram, M. S., et al. (2014). Novel synthetic biscoumarins target tumor necrosis factor-α in hepatocellular carcinoma in vitro and in vivo. Journal of Biological Chemistry, 289(46), 31879–31890. https://doi.org/10.1074/jbc.M114.593855
Cabibbo, G., Cucchetti, A., Cammà, C., Casadei-Gardini, A., Celsa, C., Rizzo, G. E. M., et al. (2019). Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials. Future Oncology, 15(29), 3411–3422. https://doi.org/10.2217/fon-2019-0287
Méndez-Blanco, C., Fondevila, F., García-Palomo, A., González-Gallego, J., & Mauriz, J. L. (2018). Sorafenib resistance in hepatocarcinoma: Role of hypoxia-inducible factors. Experimental & Molecular Medicine, 50(10), 1–9. https://doi.org/10.1038/s12276-018-0159-1
Paskeh, M. D. A., Mirzaei, S., Ashrafizadeh, M., Zarrabi, A., & Sethi, G. (2021). Wnt/β-catenin signaling as a driver of hepatocellular carcinoma progression: An emphasis on molecular pathways. Journal of Hepatocellular Carcinoma, 8, 1415.
Mohan, C. D., Anilkumar, N. C., Rangappa, S., Shanmugam, M. K., Mishra, S., Chinnathambi, A., et al. (2018). Novel 1,3,4-oxadiazole induces anticancer activity by targeting NF-κB in hepatocellular carcinoma cells. Frontiers in Oncology, 8, 42. https://doi.org/10.3389/fonc.2018.00042
Lee, J. H., Mohan, C. D., Deivasigamani, A., Jung, Y. Y., Rangappa, S., Basappa, S., et al. (2020). Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma. Journal of Advanced Research, 26, 83–94. https://doi.org/10.1016/j.jare.2020.07.004
Dai, X., Ahn, K. S., Kim, C., Siveen, K. S., Ong, T. H., Shanmugam, M. K., et al. (2015). Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3. Molecular Oncology, 9(4), 818–833. https://doi.org/10.1016/j.molonc.2014.12.008
Mohan, C. D., Bharathkumar, H., Bulusu, K. C., Pandey, V., Rangappa, S., Fuchs, J. E., et al. (2014). Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. Journal of Biological Chemistry, 289(49), 34296–34307. https://doi.org/10.1074/jbc.M114.601104
Vaid, A. K., Gupta, A., & Momi, G. (2021). Overall survival in stage IV EGFR mutation-positive NSCLC: Comparing first-, second- and third-generation EGFR-TKIs (Review). International Journal of Oncology, 58(2), 171–184. https://doi.org/10.3892/ijo.2021.5168
Yu, Y., Zeng, D., Ou, Q., Liu, S., Li, A., Chen, Y., et al. (2019). Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: A meta-analysis and individual patient-level analysis. JAMA Network Open, 2(7), e196879. https://doi.org/10.1001/jamanetworkopen.2019.6879
Stock-Martineau, S., Laurie, K., McKinnon, M., Zhang, T., & Wheatley-Price, P. (2021). Evolution of systemic treatment uptake and survival in advanced non-small cell lung cancer. Current Oncology, 28(1), 60–68.
Or, M., Liu, B., Lam, J., Vinod, S., Xuan, W., Yeghiaian-Alvandi, R., et al. (2021). A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer. Science and Reports, 11(1), 5939. https://doi.org/10.1038/s41598-021-85131-7
Ma, Z., Wang, L. Z., Cheng, J. T., Lam, W. S. T., Ma, X., Xiang, X., et al. (2021). Targeting hypoxia-inducible factor-1-mediated metastasis for cancer therapy. Antioxidants & Redox Signaling, 34(18), 1484–1497. https://doi.org/10.1089/ars.2019.7935
Guo, Y., Xiao, Z., Yang, L., Gao, Y., Zhu, Q., Hu, L., et al. (2020). Hypoxia-inducible factors in hepatocellular carcinoma. Oncology Reports, 43(1), 3–15.
Chen, C., & Lou, T. (2017). Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget, 8(28), 46691.
Bowyer, C., Lewis, A. L., Lloyd, A. W., Phillips, G. J., & Macfarlane, W. M. (2017). Hypoxia as a target for drug combination therapy of liver cancer. Anti-Cancer Drugs, 28(7), 771.
Manoochehri Khoshinani, H., Afshar, S., & Najafi, R. (2016). Hypoxia: A double-edged sword in cancer therapy. Cancer Investigation, 34(10), 536–545.
Kabakov, A. E., & Yakimova, A. O. (2021). Hypoxia-induced cancer cell responses driving radioresistance of hypoxic tumors: Approaches to targeting and radiosensitizing. Cancers (Basel), 13(5), 1102.
Harada, H. (2016). Hypoxia-inducible factor 1–mediated characteristic features of cancer cells for tumor radioresistance. Journal of Radiation Research, 57(S1), i99–i105.
Doktorova, H., Hrabeta, J., Khalil, M. A., & Eckschlager, T. (2015). Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1. Biomedical papers of the Medical Faculty of the University Palacky Olomouc Czech Republic, 159(2), 166–77.
Roy, S., Kumaravel, S., Sharma, A., Duran, C. L., Bayless, K. J., & Chakraborty, S. (2020). Hypoxic tumor microenvironment: Implications for cancer therapy. Experimental Biology and Medicine, 245(13), 1073–1086.
Dai, X., Ahn, K. S., Wang, L. Z., Kim, C., Deivasigamni, A., Arfuso, F., et al. (2016). Ascochlorin enhances the sensitivity of doxorubicin leading to the reversal of epithelial-to-mesenchymal transition in hepatocellular carcinoma. Molecular Cancer Therapeutics, 15(12), 2966–2976. https://doi.org/10.1158/1535-7163.mct-16-0391
Dai, X., Wang, L., Deivasigamni, A., Looi, C. Y., Karthikeyan, C., Trivedi, P., et al. (2017). A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma. Oncotarget, 8(8), 12831–12842. https://doi.org/10.18632/oncotarget.14606
Lee, J. H., Mohan, C. D., Shanmugam, M. K., Rangappa, S., Sethi, G., Siveen, K. S., et al. (2020). Vitexin abrogates invasion and survival of hepatocellular carcinoma cells through targeting STAT3 signaling pathway. Biochimie, 175, 58–68. https://doi.org/10.1016/j.biochi.2020.05.006
Somu, C., Mohan, C. D., Ambekar, S., Dukanya Rangappa, S., Baburajeev, C. P., et al. (2020). Identification of a novel 1,2 oxazine that can induce apoptosis by targeting NF-κB in hepatocellular carcinoma cells. Biotechnology Reports (Amst), 25, e00438. https://doi.org/10.1016/j.btre.2020.e00438
Lin, C.-A., Chang, L.-L., Zhu, H., He, Q.-J., & Yang, B. (2018). Hypoxic microenvironment and hepatocellular carcinoma treatment. Hepatoma Research, 4, 26.
Santhakumar, C., Gane, E. J., Liu, K., & McCaughan, G. W. (2020). Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatology International, 14(6), 947–957.
Xiong, X. X., Qiu, X. Y., Hu, D. X., & Chen, X. Q. (2017). Advances in hypoxia-mediated mechanisms in hepatocellular carcinoma. Molecular Pharmacology, 92(3), 246–255.
Han, D., Yang, P., Qin, B., Ji, G., Wu, Y., Yu, L., et al. (2021). Upregulation of Nogo-B by hypoxia inducible factor-1 and activator protein-1 in hepatocellular carcinoma. Cancer Science, 112(7), 2728.
Chiu, D. K. C., Xu, I. M. J., Lai, R. K. H., Tse, A. P. W., Wei, L. L., Koh, H. Y., et al. (2016). Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology, 64(3), 797–813.
Pascut, D., Pratama, M. Y., Vo, N. V., Masadah, R., & Tiribelli, C. (2020). The crosstalk between tumor cells and the microenvironment in hepatocellular carcinoma: The role of exosomal microRNAs and their clinical implications. Cancers (Basel), 12(4), 823.
留言 (0)